XML 71 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)
 1 Months Ended 12 Months Ended
Jan. 31, 2010
cvr
Dec. 31, 2023
USD ($)
Sep. 18, 2023
contract
Dec. 31, 2022
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag   Derivative assets(2)    
Number of CVR Series | cvr 4      
Primrose Bio        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Interest in potential development milestone (as a percent)     50.00%  
Primordial Genetics        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Number of contracts | contract     2  
Transferred over Time | Phase 3 clinical trial        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Gross contract asset   $ 10,000,000    
Maximum | Transferred over Time | Development, regulatory, & commercial milestones and tiered royalties        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments   375,000,000    
Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Number of CVRs issued per acquiree share | cvr 4      
Number of CVRs issued from each CVR series | cvr 1      
Frequency of cash payments to CVR holders 6 months      
Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Total liabilities       $ 84,000
Recurring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investment in Viking common stock   32,185,000   63,122,000
Derivative asset   3,531,000    
Total assets   150,886,000   166,864,000
Liability for amounts owed to a former licensor       44,000
Total liabilities   3,198,000   3,557,000
Recurring | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments, fair value   115,170,000   103,742,000
Recurring | Contingent liabilities | CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Contingent liabilities   320,000   84,000
Recurring | Contingent liabilities | Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Contingent liabilities   2,878,000   3,429,000
Recurring | Level 1        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investment in Viking common stock   32,185,000   63,122,000
Derivative asset   0    
Total assets   39,476,000   67,114,000
Liability for amounts owed to a former licensor       44,000
Total liabilities   0   44,000
Recurring | Level 1 | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments, fair value   7,291,000   3,992,000
Recurring | Level 1 | Contingent liabilities | CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Contingent liabilities   0   0
Recurring | Level 1 | Contingent liabilities | Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Contingent liabilities   0   0
Recurring | Level 2        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investment in Viking common stock   0   0
Derivative asset   0    
Total assets   107,879,000   99,615,000
Liability for amounts owed to a former licensor       0
Total liabilities   2,878,000   3,429,000
Recurring | Level 2 | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments, fair value   107,879,000   99,615,000
Recurring | Level 2 | Contingent liabilities | CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Contingent liabilities   0   0
Recurring | Level 2 | Contingent liabilities | Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Contingent liabilities   2,878,000   3,429,000
Recurring | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investment in Viking common stock   0   0
Derivative asset   3,531,000    
Total assets   3,531,000   135,000
Liability for amounts owed to a former licensor       0
Total liabilities   320,000    
Recurring | Level 3 | Short-term investments        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Investments, fair value   0   135,000
Recurring | Level 3 | Contingent liabilities | CyDex        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Contingent liabilities   320,000   84,000
Recurring | Level 3 | Contingent liabilities | Metabasis        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Contingent liabilities   $ 0   $ 0